IQVIA vs Unlearn.AI (2026)
The largest agent platform in clinical development against the most rigorous single method in it. IQVIA launched a unified agentic platform in March 2026 spanning clinical, commercial and real world evidence work, names its infrastructure stack precisely and holds the most developed governance apparatus in this category. Unlearn does one thing with unusual discipline: digital twins of trial participants used as a prognostic covariate to reduce enrolment requirements, with published method transparency approaching an academic standard and a regulatory achievement unique in this index. They are complementary, since one changes the protocol and the other runs the operation around it. The question to put to IQVIA is which of its several relationships to your data governs which capability, because it does not say.
- Its March 2026 agentic platform spans clinical, commercial and real world evidence operations with a marketplace, and the infrastructure stack is named precisely.
- The governance apparatus is the most developed in this category and includes a concrete architectural control rather than a principles page.
- For a sponsor already working across trial operations with the organisation, the agents arrive inside an existing relationship.
- Method transparency approaches an academic standard, with the procedure published and the statistical properties described rather than asserted.
- Its regulatory achievement is distinct from and arguably harder than a device clearance, and it is unique in this index.
- The autonomy question is solved by design rather than by policy, which is the most rigorous answer to it recorded here.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. IQVIA and Unlearn.AI are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | IQVIA | Unlearn.AI |
|---|---|---|
| Primary category | Clinical Trials AI | Clinical Trials AI |
| Founded | Not recorded | 2017 |
| Headquarters | Research Triangle Park, North Carolina | San Francisco, California, United States |
| Website | iqvia.com | unlearn.ai |
Side by Side
Each record in one paragraph
Written to be quoted whole. Each paragraph states what the AI Health Index verified about the vendor, with the caveats attached. Generated from this pair’s live capability grades, so it moves when a grade moves.
The AI Health Index records no top capability grade for IQVIA on any axis it scores. Set against Unlearn.AI, IQVIA grades higher on Model Supply Chain Disclosure, AI Safety and PHI Stewardship and Setting and Specialty Coverage. Its thinnest published disclosure sits on AI Liability and Recourse. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
The AI Health Index awards Unlearn.AI its top capability grade on several axes, including AI Centrality, Autonomy and Oversight Model and Model and Technology Transparency. Set against IQVIA, Unlearn.AI grades higher on several axes, including AI Centrality, Autonomy and Oversight Model and Model and Technology Transparency. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
Questions buyers ask
Should we choose IQVIA or Unlearn.AI?
On the axes where the AI Health Index separates them, IQVIA grades higher on Model Supply Chain Disclosure, AI Safety and PHI Stewardship and Setting and Specialty Coverage, and Unlearn.AI grades higher on several axes, including AI Centrality, Autonomy and Oversight Model and Model and Technology Transparency. Unlearn.AI leads on the greater share of scored axes, but the split means the decision turns on which constraint is binding rather than on an overall winner.
Where do IQVIA and Unlearn.AI differ most?
The widest separation the AI Health Index records between IQVIA and Unlearn.AI is on AI Centrality, where IQVIA grades C and Unlearn.AI grades A. That axis sits in the AI Capability group, so it should carry the most weight for a buyer whose binding constraint is how much of the work the model itself is trusted to do.
Where do IQVIA and Unlearn.AI grade the same?
The AI Health Index grades IQVIA and Unlearn.AI the same on several axes, including Clinical and Operational Evidence, HIPAA and BAA Posture and Security Certifications and Trust Center. Neither holds an advantage the index can evidence on those axes, so they should not carry weight in a selection between these two.
What have IQVIA and Unlearn.AI not disclosed?
At the last review, at least one of IQVIA and Unlearn.AI published thin or absent detail on AI Liability and Recourse. The AI Health Index treats an absent disclosure as a gap in the public record rather than a failure of the product, so these are the axes to get in writing during diligence instead of inferring from the grade.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Clinical Trials AI page.
These operate at different points, one supplying agents and services across trial operations and the other changing the statistical design of the trial itself, so they are complementary rather than competing. Unlearn's evidence measures statistical efficiency rather than patient outcomes, which is the correct claim for what it does and should not be read as clinical benefit. IQVIA stands in several relationships to sponsor data at once, as service provider, data holder and software vendor, and does not state which governs which capability. Neither publishes pricing.